Medical Education Library

An Approach to the Management of Type 2 Diabetes Mellitus in Patients Receiving Add-On Therapy With Colesevelam HCl


A supplement to Cardiology News and sponsored by Daiichi Sankyo, Inc.


• Introduction
• Results of the Glucose-Lowering Effect of WelChol Study (GLOWS): A Randomized, Double-Blind, Placebo-Controlled Pilot Study Evaluating the Effect of Colesevelam Hydrochloride on Glycemic Control in Subjects with Type 2 Diabetes
• Efficacy and Safety of Colesevelam in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Receiving Insulin-Based Therapy
• Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy
• Colesevelam Hydrochloride Therapy in Patients With Type 2 Diabetes Mellitus Treated With Metformin: Glucose and Lipid Effects

Faculty/Faculty Disclosures

Harold E. Bays, MD, FACP, FACE
Medical Director/President
Louisville Metabolic and
Atherosclerosis Research Center
Louisville, Kentucky

Dr Bays has research grants, consultant fees, and speaker fees with Abbott Laboratories, Aegerion Pharmaceuticals, Akros Pharma Inc, Amarin, Amgen Inc., Amylin Pharmaceuticals, Inc., Arena Pharmaceuticals, Inc., Arete Therapeutics Inc., AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim Corporation, Cargill, Inc., Daiichi Sankyo, Inc., Eli Lilly and Company, Essentialis, Inc., GlaxoSmithKline plc, Hoffmann-La Roche Inc., Home Access Health Corporation, InteKrin Therapeutics Inc., Isis Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc.,Merck/Schering-Plough Pharmaceuticals, Metabolex, Inc., Neuromed Pharmaceuticals Ltd., NicOx, Novo Nordisk A/S, Orexigen Therapeutics, Inc., Pfizer Inc., Purdue Pharma L.P., sanofi-aventis US LLC, Sciele Pharma, Inc., Surface Logix, Inc., Takeda Pharmaceutical Company Limited, and VIVUS Inc.

Peter H. Jones, MD
Associate Professor of Medicine
Baylor College of Medicine
Houston, Texas

Dr Jones has consulting agreements with Abbott Laboratories, AstraZeneca, Daiichi Sankyo, Inc., and Merck/Schering-Plough Pharmaceuticals.

To view the supplement, click the image above.

Recommended Reading

Hospital Readmission Risk Prediction Models Work Poorly
MDedge Cardiology
Heart Failure Hospitalization Dropped 30% Across Decade
MDedge Cardiology
Study Re-Examines ACE Inhibitor, Birth Defect Risk
MDedge Cardiology
CABG Beats PCI Regardless of SYNTAX Score
MDedge Cardiology
EMA: No Cancer Link for ARBs
MDedge Cardiology
CMS Issues Final Rule on Accountable Care Organizations
MDedge Cardiology
Measuring Quality of Care
MDedge Cardiology
ACO Details Are Out: The Policy & Practice Podcast
MDedge Cardiology
Variations in Three Genes Predict Early Stent Thrombosis
MDedge Cardiology
FDA: AF Ablation Device Effective; Safety Uncertain
MDedge Cardiology